Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Inventory: 2024-2025

Historic Inventory for ARS Pharmaceuticals (SPRY) over the last 1 years, with Sep 2025 value amounting to $7.8 million.

  • ARS Pharmaceuticals' Inventory rose 988.39% to $7.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.8 million, marking a year-over-year increase of 988.39%. This contributed to the annual value of $5.2 million for FY2024, which is N/A change from last year.
  • According to the latest figures from Q3 2025, ARS Pharmaceuticals' Inventory is $7.8 million, which was down 10.94% from $8.7 million recorded in Q2 2025.
  • ARS Pharmaceuticals' Inventory's 5-year high stood at $8.7 million during Q2 2025, with a 5-year trough of $715,000 in Q3 2024.
  • Its 2-year average for Inventory is $5.9 million, with a median of $7.3 million in 2025.
  • Data for ARS Pharmaceuticals' Inventory shows a peak YoY surged of 988.39% (in 2025) over the last 5 years.
  • Over the past 2 years, ARS Pharmaceuticals' Inventory (Quarterly) stood at $5.2 million in 2024, then surged by 988.39% to $7.8 million in 2025.
  • Its last three reported values are $7.8 million in Q3 2025, $8.7 million for Q2 2025, and $7.3 million during Q1 2025.